PRINCETON, N.J., June 25, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that its Chief Executive Officer, Nikhil Lalwani, has been named an Ernst & Young LLP (EY US) Entrepreneur Of The Year® 2024 New Jersey Award winner. Entrepreneur Of The Year is the preeminent competitive awards program for entrepreneurs and leaders of high-growth companies. Mr. Lalwani was selected by an independent judging panel made up of previous award winners, leading CEOs, a ...

PRINCETON, N.J., June 25, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that its Chief Executive Officer, Nikhil Lalwani, has been named an Ernst & Young LLP (EY US) Entrepreneur Of The Year® 2024 New Jersey Award winner. Entrepreneur Of The Year is the preeminent competitive awards program for entrepreneurs and leaders of high-growth companies. Mr. Lalwani was selected by an independent judging panel made up of previous award winners, leading CEOs, ...

Conference call scheduled for today at 8:30 a.m. ET Strengthens Rare Disease segment as largest driver of future growth, expected to add approximately $105 million in highly durable branded revenueAdds two commercial assets ILUVIEN® and YUTIQ® with significant growth potential, expanding ANI’s foothold in key strategic therapeutic area of ophthalmology Anticipated to drive high single digit to low double digit accretion in adjusted non-GAAP EPS in 2025 and to be substantially accretive thereafterExpected to ...

JHVEPhoto/iStock Editorial via Getty Images Since Ani Pharmaceuticals (NASDAQ:ANIP) merged with Biosante Pharmaceuticals in 2013, ANIP's growth has largely been fueled by M&A, the most important of which are the acquisition Purified Cortrophin Gel from Merck & Co., Inc. (MRK) in 2016 and the merger with Novitium Pharma in 2021. The market sees these as drivers of ANIP's growth, and analyst estimates currently reflect this. However, ANIP's royalty revenue potential is largely unnoticed. This article looks at ...

Pharmaceuticals, Inc. June 2024 ani © 2024 ANI Pharmaceuticals, Inc. Disclaimer To the extent any statements made in this presentation deal with information that is not historical, these are forward-looking statements within the measurg of the Private but are not limited to, those relating to the commercialization and potential sales of the product and any additional product launches from the Compory's generic pipeline, those that dillze terminology such as "anticipates," "will," "expects," "plans, " potent ...

NEW YORK, May 20, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) on behalf of the company's shareholders. The investigation seeks to determine whether ANI Pharmaceuticals's directors breached their fiduciary duties in connection with recent corporate actions.If you are a shareholder of ANI Pharmaceuticals, Inc. and are interested in obtaining additional information about your rights and options, please visit us at: https://pjlfirm.com ...

ANI Pharmaceuticals (ANIP) has been on a downward spiral lately with significant selling pressure. After declining 6.2% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a ...

BAUDETTE, Minn., May 20, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced the launch of Kionex® (Sodium Polystyrene Sulfonate Suspension USP) for Oral or Rectal use. Kionex® Suspension is the only commercially available therapeutically equivalent to the reference listed drug (RLD) SPS® Suspension for Oral or Rectal use. "The launch of Kionex® Suspension for Oral or Rectal use exemplifies our capability to bring complex generics with limited market competi ...

BAUDETTE, Minn., May 20, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Kionex® (Sodium Polystyrene Sulfonate Suspension USP) for Oral or Rectal use. Kionex® Suspension is the only commercially available therapeutically equivalent to the reference listed drug (RLD) SPS® Suspension for Oral or Rectal use. "The launch of Kionex® Suspension for Oral or Rectal use exemplifies our capability to bring complex generics with limited market compet ...

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q1 2024 Earnings Conference Call May 10, 2024 8:30 AM ET Company Participants Lisa Wilson - In-Site Communications, Investor Relations Nikhil Lalwani - President and Chief Executive Officer Stephen Carey - Senior Vice President, Finance and Chief Financial Officer Conference Call Participants Gary Nachman - Raymond James Leszek Sulewski - Truist Securities Vamil Divan - Guggenheim Securities Oren Livnat - H.C. Wainwright Timothy Chiang - Capital One Operator Good day, ...